Buy CJC1295 DAC Peptide 2mg & 5mg Vials – Premium USA Supplier

CJC-1295 DAC Peptide is a long-acting analogue related to growth hormone-releasing hormone (GHRH). The DAC modification, or Drug Affinity Complex, is designed to increase the peptide’s interaction with serum albumin, contributing to substantially longer activity than shorter-acting GHRH analogues. Research in healthy adults has investigated its pharmacokinetic and pharmacodynamic properties.

CHA Advanced Research Peptides supplies specialty research materials for qualified laboratory applications. This product listing covers 2mg and 5mg vial formats, subject to current inventory, product specifications, and available documentation.

When selecting a CJC-1295 DAC supplier, researchers should evaluate more than price. Product identity, analytical testing, batch documentation, packaging, storage requirements, shipping, and supplier transparency all matter.

Browse the CHA Research Peptide Shop to review available products.

Research-use notice: This product is offered only for lawful laboratory and research applications. It is not presented as a treatment or as an FDA-approved product, and this page does not provide human or veterinary dosing or administration instructions.

---

CJC-1295 DAC 2mg & 5mg Vial Options

This listing provides two quantity options:

• CJC-1295 DAC 2mg vial
• CJC-1295 DAC 5mg vial

Before placing an order, research buyers should verify:

• Exact product identity
• Vial quantity
• Purity specification
• Batch or lot information
• Certificate of Analysis availability
• Analytical testing
• Packaging
• Storage requirements
• Destination and shipping terms
• Wholesale availability

For product documentation or larger orders, contact CHA Advanced Research Peptides.

---

Buy CJC-1295 DAC Peptide for Research

If you’re looking for CJC-1295 DAC Peptide for research, the lowest price should not be your only purchasing criterion.

A better supplier checklist includes:

• Clearly identified product
• Defined vial quantity
• Batch information
• Analytical documentation
• Purity information
• Appropriate packaging
• Storage information
• Transparent shipping terms
• Responsive supplier support
• Wholesale purchasing options

This is especially relevant for CJC-1295 because FDA has identified concerns involving immunogenicity and peptide-related impurities and has stated that available clinical data are limited.

For common purchasing questions, visit the CHA FAQ page.

---

CJC-1295 DAC Peptide Supplier

Choosing a CJC-1295 DAC Peptide Supplier requires careful attention to product documentation and regulatory status.

CJC-1295 has been studied in humans. A randomized, placebo-controlled clinical study published in the Journal of Clinical Endocrinology & Metabolism investigated the pharmacokinetic and pharmacodynamic effects of CJC-1295 in healthy adults. The study reported sustained increases in GH and IGF-I following administration.

That research should not be converted into claims that a commercially sold research product will deliver a particular physical or medical outcome.

Current FDA information is especially relevant. FDA identifies CJC-1295 as a substance for which compounded drugs may present significant safety risks, citing potential immunogenicity, peptide-related impurities, characterization challenges, and limited clinical data. FDA also identifies serious adverse events reported in connection with CJC-1295.

Therefore, avoid claims such as:

• “FDA-approved CJC-1295”
• “Guaranteed HGH booster”
• “Builds muscle”
• “Burns fat”
• “Anti-aging treatment”
• “Improves recovery”
• “Treats growth hormone deficiency”

Those claims are not necessary to rank a product page and create avoidable regulatory and trust problems.

Learn more about CHA through the About Us page.

---

CJC-1295 DAC Research Peptide

CJC-1295 is a synthetic GHRH analogue. The DAC modification incorporates a chemical group that facilitates binding with serum albumin, helping explain its longer pharmacokinetic profile.

Human research has examined CJC-1295’s effects on GH and IGF-I concentrations. One randomized controlled study reported dose-dependent increases in GH and IGF-I in healthy adults and estimated a half-life of approximately 5.8–8.1 days.

However, these findings are research observations, not a basis for promising customers specific results.

A 2026 review of peptides affecting the GH/IGF-1 axis also emphasizes the uncertainty surrounding unapproved peptide products, including CJC-1295 DAC, and highlights concerns about product composition, safety, endocrine effects, and self-administration.

That makes transparent product documentation an important part of your commercial proposition.

---

CJC-1295 DAC 2mg Vial

The CJC-1295 DAC 2mg vial is the smaller quantity offered on this listing.

Before ordering, verify:

• 2mg quantity
• Product identity
• Purity specification
• Batch information
• Available analytical documentation
• Packaging
• Storage requirements
• Shipping conditions

For current availability, contact CHA directly.

---

CJC-1295 DAC 5mg Vial

The CJC-1295 DAC 5mg vial provides a larger listed quantity for research procurement.

Buyers should confirm:

• 5mg vial availability
• Product specifications
• Batch information
• Analytical documentation
• Packaging
• Storage requirements
• Shipping
• Wholesale availability

For larger research orders, submit a wholesale inquiry to CHA.

---

CJC-1295 DAC Wholesale Research Supply

Laboratories purchasing multiple vials may request wholesale information.

For a faster quotation, provide:

• Desired vial size
• Number of vials
• Destination
• Documentation requirements
• Packaging requirements
• Desired delivery timeframe

Wholesale pricing should be confirmed directly because inventory and batch availability can change.

Contact CHA for wholesale research supply.

---

CJC-1295 DAC Quality & Documentation

For research materials, documentation is part of the product.

Potential documentation buyers may request includes:

• Certificate of Analysis
• Batch or lot number
• Purity analysis
• Product specification
• Analytical testing information
• Packaging details
• Storage requirements

You have stated that CHA is GMP-Certified and Janoshik Verified.

Don’t make the common mistake of turning that into an unsupported blanket claim.

If the specific CJC-1295 DAC batch has a Janoshik report, link to that report or identify the applicable report clearly.

Likewise, don’t imply that GMP certification means CJC-1295 DAC is FDA-approved. Those are completely different concepts.

This distinction strengthens your E-E-A-T rather than weakening the sales page.

---

What Is CJC-1295 DAC?

CJC-1295 DAC is a modified GHRH analogue investigated for its pharmacokinetic and pharmacodynamic properties.

The “DAC” refers to the Drug Affinity Complex modification. FDA’s 2024 evaluation explains that the modification involves an MPA-bound lysine residue that enables in-vivo association with endogenous serum albumin and contributes to the longer half-life reported for CJC-1295 DAC compared with GHRH1-29.

Human research has also examined prolonged stimulation of GH and IGF-I following CJC-1295 administration.

However, current regulatory information should remain part of the context. FDA currently identifies CJC-1295 as presenting potential safety concerns when used in compounded drugs, with limited clinical data.

---

CJC-1295 DAC Peptide FAQs

What is CJC-1295 DAC?

CJC-1295 DAC is a modified analogue related to growth hormone-releasing hormone. The DAC modification contributes to longer pharmacokinetic activity through interaction with serum albumin.

What does DAC mean?

DAC means Drug Affinity Complex. It refers to the modification associated with the longer-acting CJC-1295 DAC molecule.

What vial sizes are available?

This product page covers:

• 2mg
• 5mg

Confirm current availability before purchasing.

Is CJC-1295 DAC FDA approved?

Don’t describe the CHA research product as FDA-approved.

FDA currently lists CJC-1295 among substances that may present significant safety risks when used in compounded drugs and notes limited clinical data.

Has CJC-1295 DAC been studied in humans?

Yes. Clinical research has investigated its pharmacokinetics and effects on GH and IGF-I in healthy adults.

Is CJC-1295 DAC a research peptide?

CJC-1295 has been investigated in biomedical research, including studies involving the GH/IGF-I axis.

Does CHA sell CJC-1295 DAC wholesale?

Wholesale research procurement inquiries can be submitted through the CHA contact page.

Can I request product documentation?

Contact CHA to determine which documentation is available for the particular product and batch.

Does CHA ship research peptides?

Shipping depends on destination and current shipping conditions. Review the CHA Shipping & Returns page.

Where can I find additional research peptides?

Browse the CHA Research Peptide Shop.